Safety profile of the fluoroquinolones: focus on levofloxacin.
The fluoroquinolone class of antibacterial agents are among the most frequently prescribed drugs, with utility in a broad range of bacterial infections. Although very useful agents, the fluoroquinolones as a class are associated with a number of adverse events, some with considerable clinical significance. In the past 15-20 years, tolerability concerns have led to restrictions on the use of the fluoroquinolones and, in some instances, the withdrawal of agents from the market. This review focuses on the safety and tolerability of levofloxacin, a third-generation fluoroquinolone, relative to other fluoroquinolones. A literature search was performed of the MEDLINE database encompassing the dates 1980-2009, using as keywords the drug names levofloxacin and concurrently marketed fluoroquinolones combined with the words 'safety', 'adverse effect' or 'adverse drug reaction', or the name of the specific adverse effect. Adverse events commonly associated with the fluoroquinolones include gastrointestinal and CNS toxicity (most frequently headache and dizziness), as well as other adverse events including ECG abnormalities (for example QT interval prolongation), disrupted glucose metabolism, phototoxicity, tendon and joint disorders, hypersensitivity and skin disorders, and hepatic toxicity. Package inserts for the fluoroquinolones in Europe and the US contain warnings regarding these risks. US package inserts also carry 'black-box' warnings regarding the risk of tendon rupture and joint disorders with these agents; however, there is a substantial body of evidence to indicate that there are marked differences in the tolerability profiles of the individual agents within the fluoroquinolone class. These differences may be explained, at least in part, by structural differences: all fluoroquinolones share a basic quinolone core, with differences in specific side chains underlying the adverse event relationships. Furthermore, many of the fluoroquinolone-associated adverse effects and toxicities occur more frequently in patients with pre-existing risk factors, or in certain subpopulations. Notably, package inserts for the fluoroquinolones carry warnings regarding use in the elderly, paediatric patients and patients with pre-existing, or factors predisposing to, seizure disorders. Because of this, many adverse reactions with these agents could be prevented by improving patient screening and education. The recent withdrawal of gatifloxacin due to dysglycaemia makes it timely to review the safety and tolerability of the individual agents in this class. Overall, it appears that levofloxacin is relatively well tolerated, with low rates of clinically important adverse events such as CNS toxicity, cardiovascular toxicity and dysglycaemia.
Liu
Hans H
HH
Bryn Mawr Medical Specialists, Bryn Mawr, Pennsylvania, USA.
D000328:Adult; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D002318:Cardiovascular Diseases / Q000139:chemically induced; D002493:Central Nervous System Diseases / Q000139:chemically induced; D002648:Child; D017484:Dermatitis, Phototoxic / Q000209:etiology; D004342:Drug Hypersensitivity / Q000209:etiology; D004761:Enterocolitis, Pseudomembranous / Q000139:chemically induced; D005947:Glucose; D006801:Humans; D064704:Levofloxacin; D015242:Ofloxacin / Q000009:adverse effects*; D012871:Skin Diseases / Q000139:chemically induced
D000900:Anti-Bacterial Agents; D064704:Levofloxacin; D015242:Ofloxacin; D005947:Glucose
Infection. 2000 Jul-Aug;28(4):256-7
10961538
Drug Saf. 2007;30(8):705-13
17696583
Clin Pharmacol Ther. 2003 Apr;73(4):292-303
12709719
Curr Ther Res Clin Exp. 2003 Nov;64(9):646-61
24944413
J Antimicrob Chemother. 1994 Apr;33(4):685-706
8056688
Epidemiology. 1993 Nov;4(6):496-501
8268277
Ann Pharmacother. 2001 Oct;35(10):1194-8
11675843
Vet Pathol. 1990 May;27(3):162-70
2353417
BMJ. 2002 Jun 1;324(7349):1306-7
12039823
Antimicrob Agents Chemother. 1998 Jul;42(7):1831-6
9661029
Can J Infect Dis. 2002 Jan;13(1):54-61
18159374
Drug Saf. 2008;31(4):283-92
18366239
Am Fam Physician. 2002 Feb 1;65(3):455-64
11858629
Mol Pharmacol. 2001 Jan;59(1):122-6
11125032
Med Clin North Am. 2000 Nov;84(6):1447-69
11155852
Toxicol Lett. 2009 Jan 30;184(2):81-4
19022360
Clin Infect Dis. 2005 Jul 15;41 Suppl 2:S113-9
15942877
Pharmacotherapy. 2007 Nov;27(11):1498-505
17963459
Ann Pharmacother. 2007 Nov;41(11):1859-66
17911203
Drugs. 1994 Apr;47(4):677-700
7516863
Drugs Aging. 2010 Mar 1;27(3):193-209
20210367
Curr Ther Res Clin Exp. 2004 May;65(3):225-38
24764589
Arch Intern Med. 1996 Jun 24;156(12):1327-32
8651842
Pediatr Infect Dis J. 2003 Dec;22(12):1128-32
14688586
Eur J Clin Pharmacol. 2009 Oct;65(10):959-62
19707748
Eur J Pharmacol. 2006 Dec 28;553(1-3):67-72
17070519
Pharmacotherapy. 2001 Mar;21(3):361-2
11253862
J Antimicrob Chemother. 2002 Apr;49(4):593-6
11909831
Drug Saf. 1996 Feb;14(2):69-77
8852521
J Antimicrob Chemother. 2000 May;45(5):557-9
10797074
Scand J Infect Dis. 2004;36(4):315-6
15198194
Pharmacotherapy. 2006 Jan;26(1):61-7
16509027
Eur J Pharmacol. 2004 Aug 16;497(1):111-7
15321742
Antimicrob Agents Chemother. 1993 Sep;37(9):1764-70
7902066
Clin Pharmacol Ther. 2000 Dec;68(6):658-66
11180026
Pharmacotherapy. 2001 Dec;21(12):1468-72
11765299
Clin Infect Dis. 2005 Jul 15;41 Suppl 2:S144-57
15942881
Clin Infect Dis. 2003 Nov 1;37(9):1210-5
14557966
Chemotherapy. 2001;47 Suppl 3:3-8; discussion 44-8
11549783
N Engl J Med. 2005 Dec 8;353(23):2442-9
16322602
Pediatr Infect Dis J. 2002 Jun;21(6):525-9
12182376
J Pharmacol Exp Ther. 2001 Mar;296(3):806-10
11181910
South Med J. 1994 Sep;87(9):869-74
8091248
J Infect Chemother. 2003 Dec;9(4):314-20
14691652
J Cardiovasc Electrophysiol. 2004 Apr;15(4):475-95
15090000
Drugs. 1999;58 Suppl 2:1-5
10553697
Pediatrics. 2006 Sep;118(3):1287-92
16951028
Drug Saf. 2006;29(11):1087-100
17061914
Eur J Pharmacol. 2007 Nov 14;573(1-3):70-4
17727838
Clin Ther. 2008 Jan;30(1):152-7
18343251
Clin Infect Dis. 2002 Oct 15;35(Suppl 2):S191-9
12353206
South Med J. 2001 Aug;94(8):817-24
11549195
N Engl J Med. 2004 Mar 4;350(10):1013-22
14999113
Arch Dermatol. 2004 Dec;140(12):1537-8
15611441
Drug Saf. 2009;32(5):359-78
19419232
Eur Heart J. 2000 Aug;21(15):1216-31
10924311
Drugs. 1995;49 Suppl 2:16-28
8549288
J Clin Pharmacol. 2004 May;44(5):464-73
15102866
Heart. 2003 Nov;89(11):1363-72
14594906
Drug Saf. 2006;29(5):385-96
16689555
N Engl J Med. 1995 Dec 14;333(24):1600-7
7477195
Therapie. 1996 Jul-Aug;51(4):417-8
8953820
J Antimicrob Chemother. 2003 Sep;52(3):435-40
12917247
Am J Med. 2005 Mar;118(3):259-68
15745724
Drug Saf. 2003;26(2):109-20
12534327
Pharmacotherapy. 2005 Oct;25(10):1296-302
16185172
Rev Infect Dis. 1988 Jan-Feb;10 Suppl 1:S141-6
3279489
Clin Infect Dis. 2005 Nov 1;41(9):1254-60
16206099
Europace. 2007 Sep;9 Suppl 4:iv37-44
17766322
J Antimicrob Chemother. 2000 Nov;46(5):847-8
11062213
J Antimicrob Chemother. 1996 May;37 Suppl A:145-60
8737134
Int J Antimicrob Agents. 2007 Apr;29(4):374-9
17241772
Drug Saf. 2004;27(9):671-86
15230648
JAMA. 1993 Jun 2;269(21):2765-8
8492403
Pharmacol Ther. 1995 Jun;66(3):465-505
7494856
Epilepsia. 1993 May-Jun;34(3):453-68
8504780
Aliment Pharmacol Ther. 2006 Oct 15;24(8):1187-95
17014577
Arch Intern Med. 2000 Oct 9;160(18):2819-22
11025792
Clin Infect Dis. 2004 Mar 1;38(5):640-5
14986246
Ann Noninvasive Electrocardiol. 2006 Jan;11(1):52-6
16472283
South Med J. 2006 Jan;99(1):52-6
16466123
Fundam Appl Toxicol. 1988 Jul;11(1):110-9
3209009
J Antimicrob Chemother. 2006 Oct;58(4):891-4
16880172
J Infect Chemother. 2006 Apr;12(2):109-11
16648952
J Antimicrob Chemother. 1990 Nov;26 Suppl D:31-44
2286589
Eur J Pharmacol. 2000 Oct 20;406(3):341-3
11040340
Am Fam Physician. 2000 May 1;61(9):2741-8
10821154
Expert Opin Pharmacother. 2002 Sep;3(9):1251-66
12186618
J Chemother. 2006 Apr;18(2):127-39
16736880
Eur J Obstet Gynecol Reprod Biol. 2009 Apr;143(2):75-8
19181435
Chest. 2005 Nov;128(5):3398-406
16304291
Pharmacotherapy. 2005 Oct;25(10):1303-9
16185173
Arch Intern Med. 2003 Aug 11-25;163(15):1801-7
12912715
Clin Ther. 2004 Jul;26(7):940-50
15336463
N Engl J Med. 2006 Mar 30;354(13):1352-61
16510739
Am J Hematol. 2000 Jan;63(1):28-31
10602164
Drug Saf. 1999 Nov;21(5):407-21
10554054
Clin Infect Dis. 1999 Feb;28(2):352-64
10064255
Expert Opin Pharmacother. 2006 Apr;7(6):639-51
16556082
Br J Pharmacol. 2008 Aug;154(7):1538-43
18500356
Cell. 1995 Apr 21;81(2):299-307
7736582
Indian J Physiol Pharmacol. 1997 Apr;41(2):164-6
9142563
Am J Clin Dermatol. 2002;3(7):509-16
12180900